Summit Therapeutics Inc.: insider trades · United States · SEC (Form 4)

About Summit Therapeutics Inc.

Summit Therapeutics Inc. is a U.S.-listed biopharmaceutical company traded on the NASDAQ under the ticker SMMT; it is headquartered in Miami, Florida, United States. Founded in 2003, the company has evolved from a broader pharmaceutical development profile into a highly focused oncology platform centered on late-stage clinical development and, ultimately, commercialization. For French-, Belgian- and Swiss-based investors, Summit should be viewed less as a diversified pharma group and more as a development-stage biotech with a concentrated risk/reward profile tied to a small number of key clinical and regulatory milestones. The company’s lead asset is ivonescimab, an investigational bispecific antibody that combines PD-1 blockade with VEGF inhibition in a single molecule. Summit licenses rights to develop and commercialize ivonescimab in its core territories from Akeso, and within Summit’s licensed territory the molecule is also referred to as SMT112. The current investment case is therefore driven primarily by one franchise, with the company building clinical evidence in non-small cell lung cancer (NSCLC) and expanding into additional solid tumor settings through phase III programs and external collaborations. Strategically, Summit is attempting to differentiate itself through a potential first-in-class or best-in-class mechanism that may offer a more convenient and potentially more effective alternative to existing immuno-oncology combinations. Summit’s geographic footprint is international, with headquarters in Miami and additional offices in Menlo Park, Princeton, Dublin, and Oxford. This structure supports global clinical development, operational execution, and regulatory engagement. The company’s most important market remains the United States, where it is pursuing FDA approval and building a commercial infrastructure alongside its late-stage clinical program. The NASDAQ listing also places Summit squarely within the U.S. biotech investor universe, where clinical catalysts and regulatory readouts are typically major valuation drivers. Recent news flow has been material. In January 2026, the FDA accepted Summit’s Biologics License Application for ivonescimab in combination with chemotherapy in EGFR-mutated NSCLC after prior TKI therapy, and the company cited a PDUFA target action date of November 14, 2026. Around the same time, Summit announced a clinical trial collaboration with GSK to evaluate ivonescimab with GSK’s B7-H3 ADC across multiple solid tumor settings, including small cell lung cancer. During 2025, Summit reported additional phase III progress and efficacy updates, reinforcing the view that the company is moving deeper into the pivotal-stage phase of its development story. In short, SMMT is a specialized oncology biotech whose valuation is likely to remain highly sensitive to clinical outcomes, FDA review progress, and the commercial potential of ivonescimab.